According to a new research report by RNCOS, “Global Obesity Drug Market Analysis”, obesity has developed into a key global epidemic over the last few decades. Backed by rising health concerns and increasing consumer spending on healthcare services, the global obesity drug market reached the estimated market size of around US$ 1.7 Billion in 2011 and is further anticipated to grow at a CAGR of around 13% during 2012-2014. The main reason for this double digit growth will be the rapidly increasing prevalence of the disease globally.
We have found that over the last few years, obesity has been recognized as a national health threat and a key public health challenge in the US. In the future, therefore, the US is expected to provide maximum opportunity to players in obesity drug market as the prevalence of obesity in the country surged from 19.4% in 1997 to 26.7% in 2009 and is forecasted to increase to a staggering 41% by 2015-end. Thus, the key drivers, government role, and key statistics with regards to US obesity drug market are evaluated prudently in this report.
The report, “Global Obesity Drug Market Analysis”, provides an effective insight into the global obesity drug market by investigating the current market trends and their impact on the industry performance. It also presents an illustration about the new treatments that are emerging in the global market. The report further elaborates in a comprehensive manner the current state of global obesity drug market and provides future outlook by 2014, taking into account key industry developments.
The report is an outcome of an extensive research and prudent analysis of the global obesity drug market facilitating reliable statistics on the major obesity drugs in the market and the revenue patterns. It also presents highlight on the key obesity drugs holding tremendous growth potential and which are in pipeline at present. An in-depth analysis of the market development in key regions of the world has also been analyzed in the report. Overall, the report is a comprehensive study of the global obesity market and is likely to provide clients with an optimum source of knowledge and statistics on the global obesity drug market.
F or more Information visit: http://www.rncos.com/Report/IM335.htm |
